放射性治疗后盆腔复发性宫颈癌患者行碘 125 粒子植入治疗的疗效及安全性：中国患者单臂荟萃分析
Efficacy and Safety of I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single-Arm Meta-Analysis of Chinese Patients.
机构信息
Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
出版信息
Cancer Rep (Hoboken). 2024 Aug;7(8):e2147. doi: 10.1002/cnr2.2147.
BACKGROUND
The study aimed to assess the efficacy and safety of I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy. This meta-analysis was registered in PROSPERO. We looked up relevant studies in the databases of CNKI, Wanfang, CBM, PubMed, Embase, Cochrane Library, and Web of Science. The endpoint measures include the objective response rate, disease control rate, progression-free survival, overall survival, and adverse events.
RECENT FIDINGS
The meta-analysis included six studies and a total of 246 patients. The pooled ORR of tumor response was 63%, and the DCR was 87%. The median PFS was 9.09 months, and the median OS was 13.46 months. The incidence of adverse events of Grade ≥III was 6%.
CONCLUSION
In conclusion, this meta-analysis confirmed that I seed implantation has a good local control rate and high safety in the treatment of pelvic recurrent cervical cancer following radiotherapy, and can be used as a remedial treatment for pelvic recurrent cervical cancer following radiotherapy to prolong the survival time of patients.
TRIAL REGISTRATION
PROSPERO: CRD42023423857.
背景
本研究旨在评估~125Ⅰ粒子植入治疗放疗后盆腔复发性宫颈癌的疗效和安全性。本研究已在 PROSPERO 注册。我们检索了中国知网、万方、CBM、PubMed、Embase、Cochrane 图书馆和 Web of Science 数据库中的相关研究。终点指标包括客观缓解率、疾病控制率、无进展生存期、总生存期和不良事件。
最近发现
该荟萃分析纳入了 6 项研究，共 246 例患者。肿瘤反应的汇总客观缓解率为 63%，疾病控制率为 87%。中位无进展生存期为 9.09 个月，中位总生存期为 13.46 个月。≥Ⅲ级不良事件的发生率为 6%。
结论
综上所述，本荟萃分析证实，~125Ⅰ粒子植入治疗放疗后盆腔复发性宫颈癌具有较好的局部控制率和较高的安全性，可作为放疗后盆腔复发性宫颈癌的补救性治疗方法，延长患者的生存时间。
试验注册
PROSPERO：CRD42023423857。
Zotero 插件